This work was presented in part at the 2006 American Geriatric Society Annual Scientific Meeting, Chicago, Illinois, and the 2005 American Society of Hematology 47th Annual Meeting and Exposition, Atlanta, Georgia.
Chronic Anemia and Fatigue in Elderly Patients: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Exploratory Study with Epoetin Alfa
Article first published online: 14 AUG 2007
Journal of the American Geriatrics Society
Volume 55, Issue 10, pages 1557–1565, October 2007
How to Cite
Agnihotri, P., Telfer, M., Butt, Z., Jella, A., Cella, D., Kozma, C. M., Ahuja, M., Riaz, S. and Akamah, J. (2007), Chronic Anemia and Fatigue in Elderly Patients: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Exploratory Study with Epoetin Alfa. Journal of the American Geriatrics Society, 55: 1557–1565. doi: 10.1111/j.1532-5415.2007.01357.x
- Issue published online: 14 AUG 2007
- Article first published online: 14 AUG 2007
- epoetin alfa
OBJECTIVES: To evaluate the effect of epoetin alfa treatment on hemoglobin (Hb), fatigue, quality of life (QOL), and mobility in elderly patients with chronic anemia.
DESIGN: An exploratory, 32 week, randomized, double-blind, crossover treatment trial.
PARTICIPANTS: Sixty-two community-dwelling individuals aged 65 and older with chronic anemia (Hb ≤11.5 g/dL).
INTERVENTION: Subcutaneous epoetin alfa or placebo weekly for 16 weeks (Phase I) with crossover to the opposite treatment (Phase II).
MEASUREMENTS: Hb and QOL scores from the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Mobility was assessed as a secondary outcome using the Timed Up and Go (TUG) test.
RESULTS: Of the 62 subjects enrolled, complete data were analyzed for 58 in Phase I and 54 participants in Phase II. Of those enrolled, most were African American (95%) and female (85%) and had multiple comorbidities and a mean age±standard deviation of 76.1±7.2. Mean baseline Hb was 10.5±0.9 g/dL (7.3–11.5). In Phase I, 67% of those taking epoetin alfa, and in Phase II, 69% of those taking epoetin alfa had an increase in Hb of more than 2 g/dL, significantly more than those taking placebo (P<.001). Similarly, elderly participants significantly improved on the fatigue and anemia subscales of the FACIT across phases (all P<.05). No significant differences were found between treatment and placebo on TUG scores. Epoetin alfa was well tolerated.
CONCLUSION: In this trial involving predominantly older African-American women with anemia, a direct relationship existed between increases in Hb during epoetin alfa therapy and improvements in fatigue and QOL.